Complex analysis of the p53 tumor suppressor in lung carcinoma
Jazyk angličtina Země Řecko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26718964
DOI
10.3892/or.2015.4533
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom plic MeSH
- adenokarcinom genetika patologie MeSH
- dospělí MeSH
- hybridizace in situ fluorescenční MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorová transformace buněk genetika MeSH
- nádorový supresorový protein p53 genetika MeSH
- nádory plic genetika patologie MeSH
- nemalobuněčný karcinom plic genetika patologie MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- regulace genové exprese u nádorů MeSH
- senioři MeSH
- spinocelulární karcinom genetika patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- nádorový supresorový protein p53 MeSH
Lung cancer is the leading cause of cancer-related deaths worldwide. The p53 tumor suppressor is a transcription factor controlling expression of its target genes in response to various stress stimuli. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Pathology University Hospital Brno Czech Republic
Department of Respiratory Diseases and TB University Hospital Brno Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org